Understanding chronic GVHD from different angles.
作者信息
Blazar Bruce, White Eric S, Couriel Daniel
机构信息
Pediatric Blood and Marrow Transplantation Program, University of Minnesota, Ann Arbor, MI 48109, USA.
出版信息
Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S184-8. doi: 10.1016/j.bbmt.2011.10.025.
Abstract
摘要
相似文献
1
Understanding chronic GVHD from different angles.
Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S184-8. doi: 10.1016/j.bbmt.2011.10.025.
2
Immune Modulation Properties of Zoledronic Acid on TcRγδ T-Lymphocytes After TcRαβ/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia.
Front Immunol. 2020 May 12;11:699. doi: 10.3389/fimmu.2020.00699. eCollection 2020.
3
Alemtuzumab for the prevention and treatment of graft-versus-host disease.
Int J Hematol. 2011 May;93(5):586-593. doi: 10.1007/s12185-011-0802-2. Epub 2011 Mar 3.
4
Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Jun;25(6):1260-1268. doi: 10.1016/j.bbmt.2019.01.029. Epub 2019 Jan 30.
5
Isolated orbital relapse of multiple myeloma in a patient with severe chronic GVHD after allogeneic hematopoietic SCT.
Bone Marrow Transplant. 2014 Jul;49(7):988-9. doi: 10.1038/bmt.2014.81. Epub 2014 Apr 28.
6
7
Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Biol Blood Marrow Transplant. 2017 Sep;23(9):1498-1508. doi: 10.1016/j.bbmt.2017.05.026. Epub 2017 May 26.
8
[GVHD and GVL].
Rinsho Ketsueki. 2009 Oct;50(10):1407-19.
9
Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum.
Biol Blood Marrow Transplant. 2015 Dec;21(12):2035-2036. doi: 10.1016/j.bbmt.2015.10.007. Epub 2015 Oct 14.
10
Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Biol Blood Marrow Transplant. 2010 Mar;16(3):320-32. doi: 10.1016/j.bbmt.2009.10.006. Epub 2009 Oct 14.
引用本文的文献
1
Multiple mononeuritis as a manifestation of graft versus host disease.
Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):473-476. doi: 10.1016/j.htct.2022.02.009. Epub 2022 Apr 10.
2
Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease.
Front Immunol. 2019 Oct 18;10:2470. doi: 10.3389/fimmu.2019.02470. eCollection 2019.
3
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3.
4
Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
Int J Hematol. 2015 May;101(5):438-51. doi: 10.1007/s12185-015-1782-4. Epub 2015 Mar 27.
5
Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD.
Bone Marrow Transplant. 2014 Apr;49(4):532-8. doi: 10.1038/bmt.2013.225. Epub 2014 Jan 27.
本文引用的文献
1
The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.
Haematologica. 2011 Nov;96(11):1678-84. doi: 10.3324/haematol.2011.049841. Epub 2011 Jul 26.
2
Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Int J Hematol. 2011 Apr;93(4):532-541. doi: 10.1007/s12185-011-0820-0. Epub 2011 Apr 5.
3
Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.
Blood. 2011 Apr 28;117(17):4651-7. doi: 10.1182/blood-2010-11-319509. Epub 2011 Feb 25.
4
Chronic graft-versus-host disease (GVHD) in children.
Pediatr Clin North Am. 2010 Feb;57(1):297-322. doi: 10.1016/j.pcl.2009.11.003.
5
Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.
Bone Marrow Transplant. 2010 Jul;45(7):1174-80. doi: 10.1038/bmt.2009.320. Epub 2009 Nov 16.
6
Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S106-14. doi: 10.1016/j.bbmt.2009.11.002. Epub 2009 Nov 5.
7
Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.
Biol Blood Marrow Transplant. 2009 Sep;15(9):1005-13. doi: 10.1016/j.bbmt.2009.04.003. Epub 2009 Jun 10.
8
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
Blood. 2009 Apr 16;113(16):3865-74. doi: 10.1182/blood-2008-09-177840. Epub 2009 Jan 23.
9
Feasibility of NIH consensus criteria for chronic graft-versus-host disease.
Leukemia. 2009 Jan;23(1):78-84. doi: 10.1038/leu.2008.276. Epub 2008 Oct 2.
10
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
Biol Blood Marrow Transplant. 2008 Oct;14(10):1163-1171. doi: 10.1016/j.bbmt.2008.07.015.
Zotero 插件